News

Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study showed that add-on treatment with once-daily anti-epileptic Zebinix (eslicarbazepine acetate; ESL), resulted in a sustained

Yaupon has completed enrollment for a pivotal phase-II clinical trial for Clearazide, for the treatment of early-stage cutaneous T-cell lymphoma (CTCL – stages 1-2a). The randomized, double-blind, controlled

YM BioSciences has reported that it’s subsidiary CIMYM BioSciences, and Oncoscience have resolved the issues between the companies. CIMYM has formally notified Oncoscience that it no longer intends

Hospira has received FDA approval for a 500mg vial of azithromycin for injection, in the ADD-Vantage System. The anti-infective medication is a generic version of Pfizer’s Zithromax for

Abraxis has received a recommendation from the Quebec Conseil du Medicament and approval from the Quebec Ministry of Health for Abraxane, for Injectable Suspension 100mg in Quebec. It

Sinovac has received a revised Drug Supplementary Application Approval (SAA) for Panflu, company’s pandemic influenza vaccine, from SFDA, based on the phase-IIb clinical trial. Under the revised approval,

Cordex has completed the production of the ATPace clinical trial material (CTM), in preparation for planned pivotal clinical trials. The protocol of these clinical trials has been approved

ImmunoCellular (IMUC) has reported the issuance of a Japanese patent relating to the company’s monoclonal antibody therapeutics. Patent No. 4287147 is titled Monoclonal Antibodies and Cell Surface Antigens

Mylan has collaborated with Biocon on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds for the global marketplace. As part of the collaboration, Mylan